Weight Watchers Launches Wegovy Oral Medication at $149 Monthly Fee
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy WW?
Source: Globenewswire
- Expanded Drug Access: Weight Watchers introduces Novo Nordisk's newly FDA-approved Wegovy oral medication through its GLP-1 platform, reinforcing its leadership in integrated care models that help users succeed with medication.
- Significant Outcomes: Members of Weight Watchers Med+ who engaged with the GLP-1 Success Program lost an average of 61.3% more body weight, demonstrating the effectiveness of combining behavioral support with medication, thereby enhancing customer satisfaction and loyalty.
- Clear Market Positioning: The launch of the Wegovy oral medication offers a more convenient option for patients hesitant about injectable therapies, with a monthly fee of $149 lowering the entry barrier and attracting more users seeking clinically supported weight management.
- Deepened Strategic Collaboration: Weight Watchers' partnership with Novo Nordisk aligns on education and drug access while ensuring ongoing support beyond prescriptions, further solidifying its market position in weight management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WW
Wall Street analysts forecast WW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WW is 38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 19.150
Low
38.00
Averages
38.00
High
38.00
Current: 19.150
Low
38.00
Averages
38.00
High
38.00
About WW
WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon Enters GLP-1 Drug Market, Competing with Pharma Giants
- Intensifying Market Competition: Pharmaceutical giants Eli Lilly and Novo Nordisk are competing in the GLP-1 drug space, particularly as Novo Nordisk is set to regain market share by launching the oral version of Wegovy in 2026, which could shift overall market dynamics.
- Amazon's Market Opportunity: Amazon has begun selling the oral version of Wegovy, with monthly costs as low as $25 for insured customers and $149 for uninsured ones, positioning itself to capture significant retail market share due to its vast customer base and convenient purchasing options.
- Shifting Consumer Preferences: The introduction of oral GLP-1 drugs is expected to encourage more consumers to try these medications for weight loss, driving overall demand and benefiting all companies involved in this sector.
- Impact on Competitive Landscape: Companies like Hims & Hers, WW International, and GoodRx face tough competition, especially as GLP-1 drugs gain popularity; Amazon's 200 million Prime members provide it with a substantial advantage in the e-commerce space, potentially leading to a decline in market share for other competitors.
See More
Novo Nordisk's Oral Wegovy Hits Record 20,371 Prescriptions in Second Week, Nearly 500% Surge
- Prescription Surge: Novo Nordisk's oral Wegovy reached 20,371 prescriptions in its second week, a nearly 500% increase from 4,289 in the first week, indicating rapid market acceptance that could reshape revenue trajectories in the weight-loss drug market.
- Significant Market Potential: This figure is likely conservative as retail prescription data excludes Novo Nordisk's direct-to-consumer channels and telehealth platforms, suggesting actual demand could be double or triple the reported number, indicating a larger market opportunity.
- Clear Competitive Advantage: With distribution in over 70,000 retail locations, Novo Nordisk has established brand loyalty before Eli Lilly's oral competitor, Orforglipron, is set to launch in 2026, giving Novo a significant first-mover advantage.
- Industry Transformation Signal: The mainstream adoption of oral GLP-1 drugs could dramatically expand the total addressable market for weight-loss medications, altering revenue trajectories for both Novo and Lilly, with increasing market attention suggesting Wall Street may be underestimating the potential explosion in this sector.
See More
Amazon Launches Novo Nordisk's Wegovy Weight-Loss Pill with Monthly Costs Starting at $25
- Drug Launch: Amazon has introduced Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy, with cash-paying patients facing a monthly cost starting at $149, while insured patients can access it for as low as $25, significantly lowering the barrier to obesity medication access and likely attracting more consumers.
- Market Expansion: The launch of the Wegovy pill marks Novo Nordisk's first oral GLP-1 drug release in the U.S., aiming to disrupt the dominance of traditional injectable medications and further expand its customer base while increasing market share.
- Strategic Partnerships: Since its launch in 2020, Amazon Pharmacy has collaborated with companies like WeightWatchers and Eli Lilly to deliver weight-loss medications, with analysts estimating annual revenue could reach $2 billion, thereby solidifying its position in the U.S. healthcare sector.
- Convenient Services: Amazon promises same-day prescription delivery for nearly half of U.S. consumers, and this strategy of rapid delivery and price transparency is expected to enhance user experience and attract more users to its pharmacy services.
See More
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
- Significant Weight Loss Efficacy: The Wegovy pill demonstrates an average weight loss of approximately 17% (16.6%) when combined with a reduced-calorie diet and exercise, compared to only 3% (2.7%) for the placebo, indicating strong market potential that could drive Novo Nordisk's sales growth.
- Diverse Purchasing Channels: Wegovy is available through various outlets, including CVS and Costco, with a starting dose of 1.5 mg priced at around $149 per month, ensuring patient accessibility and expanding market coverage.
- Price Strategy Adjustment: Novo Nordisk has halved Wegovy prices in China ahead of impending generic competition, a strategy that not only enhances market competitiveness but may also attract more consumers to choose its products.
- Stock Performance Recovery: Novo Nordisk shares rose 4.14% to $54.55, although still trading 8.4% below the 200-day SMA, the recent strong performance may attract more investor interest and boost market confidence.
See More
Novo Nordisk Launches First GLP-1 Weight Loss Pill in the U.S. Starting at $149/Month
- First Oral Weight Loss Drug: Novo Nordisk launched the Wegovy pill, the first GLP-1 oral weight loss medication in the U.S. on Monday, marking a new chapter in obesity treatment and offering new options for over 100 million Americans living with obesity.
- Significant Price Advantage: The drug's cash prices range from $149 to $299 per month, significantly lower than the approximately $1,000 monthly cost of injection therapies, which is expected to address long-standing affordability issues and expand market access.
- Huge Market Potential: Analysts predict that oral drugs could capture a 24% share, or around $22 billion, of the global weight loss drug market by 2030, giving Novo Nordisk a competitive edge in the rapidly growing GLP-1 space.
- Notable Clinical Efficacy: In a phase three trial involving over 300 adults with obesity, the highest dose of the oral drug led to an average weight loss of 16.6% after 64 weeks, demonstrating its effectiveness and solidifying Novo Nordisk's leadership position in the weight loss drug market.
See More
Weight Watchers Launches Wegovy Oral Medication at $149 Monthly Fee
- Expanded Drug Access: Weight Watchers introduces Novo Nordisk's newly FDA-approved Wegovy oral medication through its GLP-1 platform, reinforcing its leadership in integrated care models that help users succeed with medication.
- Significant Outcomes: Members of Weight Watchers Med+ who engaged with the GLP-1 Success Program lost an average of 61.3% more body weight, demonstrating the effectiveness of combining behavioral support with medication, thereby enhancing customer satisfaction and loyalty.
- Clear Market Positioning: The launch of the Wegovy oral medication offers a more convenient option for patients hesitant about injectable therapies, with a monthly fee of $149 lowering the entry barrier and attracting more users seeking clinically supported weight management.
- Deepened Strategic Collaboration: Weight Watchers' partnership with Novo Nordisk aligns on education and drug access while ensuring ongoing support beyond prescriptions, further solidifying its market position in weight management.
See More
Amazon Enters GLP-1 Drug Market, Competing with Pharma Giants
- Intensifying Market Competition: Pharmaceutical giants Eli Lilly and Novo Nordisk are competing in the GLP-1 drug space, particularly as Novo Nordisk is set to regain market share by launching the oral version of Wegovy in 2026, which could shift overall market dynamics.
- Amazon's Market Opportunity: Amazon has begun selling the oral version of Wegovy, with monthly costs as low as $25 for insured customers and $149 for uninsured ones, positioning itself to capture significant retail market share due to its vast customer base and convenient purchasing options.
- Shifting Consumer Preferences: The introduction of oral GLP-1 drugs is expected to encourage more consumers to try these medications for weight loss, driving overall demand and benefiting all companies involved in this sector.
- Impact on Competitive Landscape: Companies like Hims & Hers, WW International, and GoodRx face tough competition, especially as GLP-1 drugs gain popularity; Amazon's 200 million Prime members provide it with a substantial advantage in the e-commerce space, potentially leading to a decline in market share for other competitors.
See More
Novo Nordisk's Oral Wegovy Hits Record 20,371 Prescriptions in Second Week, Nearly 500% Surge
- Prescription Surge: Novo Nordisk's oral Wegovy reached 20,371 prescriptions in its second week, a nearly 500% increase from 4,289 in the first week, indicating rapid market acceptance that could reshape revenue trajectories in the weight-loss drug market.
- Significant Market Potential: This figure is likely conservative as retail prescription data excludes Novo Nordisk's direct-to-consumer channels and telehealth platforms, suggesting actual demand could be double or triple the reported number, indicating a larger market opportunity.
- Clear Competitive Advantage: With distribution in over 70,000 retail locations, Novo Nordisk has established brand loyalty before Eli Lilly's oral competitor, Orforglipron, is set to launch in 2026, giving Novo a significant first-mover advantage.
- Industry Transformation Signal: The mainstream adoption of oral GLP-1 drugs could dramatically expand the total addressable market for weight-loss medications, altering revenue trajectories for both Novo and Lilly, with increasing market attention suggesting Wall Street may be underestimating the potential explosion in this sector.
See More
Amazon Launches Novo Nordisk's Wegovy Weight-Loss Pill with Monthly Costs Starting at $25
- Drug Launch: Amazon has introduced Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy, with cash-paying patients facing a monthly cost starting at $149, while insured patients can access it for as low as $25, significantly lowering the barrier to obesity medication access and likely attracting more consumers.
- Market Expansion: The launch of the Wegovy pill marks Novo Nordisk's first oral GLP-1 drug release in the U.S., aiming to disrupt the dominance of traditional injectable medications and further expand its customer base while increasing market share.
- Strategic Partnerships: Since its launch in 2020, Amazon Pharmacy has collaborated with companies like WeightWatchers and Eli Lilly to deliver weight-loss medications, with analysts estimating annual revenue could reach $2 billion, thereby solidifying its position in the U.S. healthcare sector.
- Convenient Services: Amazon promises same-day prescription delivery for nearly half of U.S. consumers, and this strategy of rapid delivery and price transparency is expected to enhance user experience and attract more users to its pharmacy services.
See More
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
- Significant Weight Loss Efficacy: The Wegovy pill demonstrates an average weight loss of approximately 17% (16.6%) when combined with a reduced-calorie diet and exercise, compared to only 3% (2.7%) for the placebo, indicating strong market potential that could drive Novo Nordisk's sales growth.
- Diverse Purchasing Channels: Wegovy is available through various outlets, including CVS and Costco, with a starting dose of 1.5 mg priced at around $149 per month, ensuring patient accessibility and expanding market coverage.
- Price Strategy Adjustment: Novo Nordisk has halved Wegovy prices in China ahead of impending generic competition, a strategy that not only enhances market competitiveness but may also attract more consumers to choose its products.
- Stock Performance Recovery: Novo Nordisk shares rose 4.14% to $54.55, although still trading 8.4% below the 200-day SMA, the recent strong performance may attract more investor interest and boost market confidence.
See More
Novo Nordisk Launches First GLP-1 Weight Loss Pill in the U.S. Starting at $149/Month
- First Oral Weight Loss Drug: Novo Nordisk launched the Wegovy pill, the first GLP-1 oral weight loss medication in the U.S. on Monday, marking a new chapter in obesity treatment and offering new options for over 100 million Americans living with obesity.
- Significant Price Advantage: The drug's cash prices range from $149 to $299 per month, significantly lower than the approximately $1,000 monthly cost of injection therapies, which is expected to address long-standing affordability issues and expand market access.
- Huge Market Potential: Analysts predict that oral drugs could capture a 24% share, or around $22 billion, of the global weight loss drug market by 2030, giving Novo Nordisk a competitive edge in the rapidly growing GLP-1 space.
- Notable Clinical Efficacy: In a phase three trial involving over 300 adults with obesity, the highest dose of the oral drug led to an average weight loss of 16.6% after 64 weeks, demonstrating its effectiveness and solidifying Novo Nordisk's leadership position in the weight loss drug market.
See More
Weight Watchers Launches Wegovy Oral Medication at $149 Monthly Fee
- Expanded Drug Access: Weight Watchers introduces Novo Nordisk's newly FDA-approved Wegovy oral medication through its GLP-1 platform, reinforcing its leadership in integrated care models that help users succeed with medication.
- Significant Outcomes: Members of Weight Watchers Med+ who engaged with the GLP-1 Success Program lost an average of 61.3% more body weight, demonstrating the effectiveness of combining behavioral support with medication, thereby enhancing customer satisfaction and loyalty.
- Clear Market Positioning: The launch of the Wegovy oral medication offers a more convenient option for patients hesitant about injectable therapies, with a monthly fee of $149 lowering the entry barrier and attracting more users seeking clinically supported weight management.
- Deepened Strategic Collaboration: Weight Watchers' partnership with Novo Nordisk aligns on education and drug access while ensuring ongoing support beyond prescriptions, further solidifying its market position in weight management.
See More
